Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin
- 2 April 2007
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (12) , 3384-3387
- https://doi.org/10.1016/j.bmcl.2007.03.095
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2006
- Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2006
- Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 DiabetesAnnals of Internal Medicine, 2005
- (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 DiabetesJournal of Medicinal Chemistry, 2004
- Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2004
- Incretins, insulin secretion and Type 2 diabetes mellitusDiabetologia, 2004
- Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VIIBiochemical Journal, 2003
- The Glucagon-Like PeptidesEndocrine Reviews, 1999
- Glucagon-like peptidesDiabetes, 1998
- Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IVEndocrinology, 1995